Hasebe, Masashi
Yoshiji, Satoshi
Keidai, Yamato
Minamino, Hiroto
Murakami, Takaaki
Tanaka, Daisuke
Fujita, Yoshihito
Harada, Norio
Hamasaki, Akihiro
Inagaki, Nobuya
Article History
Received: 18 January 2023
Accepted: 14 February 2023
First Online: 19 March 2023
Change Date: 24 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12933-023-01825-4
Declarations
:
: Does not involve ethical approval and consent.
: Not applicable.
: NI received research funds from Terumo Corp., Drawbridge, Inc., and Asken Inc. NI received speaker honoraria from Kowa Co., Ltd., MSD K. K, Astellas Pharma Inc., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Sumitomo Dainippon Pharma Co., Ltd., Sanofi K.K., and Eli Lilly Japan K.K.; received a scholarship grant from Kissei Pharmaceutical Co., Ltd., Sanofi K.K., Daiichi-Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co., Ltd., Japan Tobacco Inc., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Astellas Pharma Inc., MSD K.K., Ono Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd., Novartis Pharma K.K., and Life Scan Japan K.K. NI is an advisory board member of Novo Nordisk. NI and NH were investigators for the SUSTAIN and PIONEER programs. Other authors declare no conflicts of interests.